News | December 08, 2011

OmniVision's High-Performance Camera Supports Medicare-Accepted Disposable Medical Device

December 8, 2011 – OmniVision, a developer of advanced digital imaging solutions, announced that its ultra-compact, high-performance OV6930 CMOS image sensor performed exceptionally well in a recent 448-patient clinical study on Avantis Medical Systems' Third Eye Retroscope. The study, published in the March issue of Gastrointestinal Endoscopy, demonstrates that the Third Eye Retroscope can increase the accuracy in diagnosing adenomas, or pre-cancerous polyps, by 23.2 percent when used in conjunction with a traditional colonoscope.(1)

The Third Eye Retroscope is a U.S. Food and Drug Administration (FDA)-cleared, disposable, catheter-based camera for use with a standard colonoscope that provides a continuous backward-looking view while the colonoscope provides the usual forward view. In 2010, Avantis received a Medicare and Medicaid reimbursement code for the Third Eye Retroscope. The companies believe that this recognition by Medicare and Medicaid, combined with the favorable results from this recent clinical study, may significantly accelerate the adoption rate by healthcare providers in the United States.

"The OV6930's excellent low-light sensitivity and image quality enabled the Third Eye to perform extraordinarily well in the clinical study, drastically improving colonoscopy accuracy," said Matthew Whitcombe, senior marketing manager at OmniVision. "Moreover, by providing this superior performance in a form factor with an exceedingly small footprint, the OV6930 allows for ultra-compact camera designs, making these medical procedures minimally invasive for the patient."

"With currently more than 150,000 cases of colorectal cancer reported annually in the U.S., and more than 400,000 in Europe, it is the second-leading cause of cancer-related deaths in the U.S. and Europe," said Doug Gielow, vice president of sales and marketing at Avantis. "However, using today's advanced imaging technologies, it can be highly preventable through early detection. Now that this product is Medicare-approved, we hope to see greater adoption of this technology by healthcare providers, who can now submit claims for reimbursement."

The OV6930 is a CMOS image sensor designed specifically for use in medical devices. With a packaged footprint of only 1.8 x 1.8 mm, the OV6930 is an ideal solution for endoscopic applications that require a small profile, including bronchoscopy, colonoscopy, gastroscopy, OB-GYN and urology. It combines ultra-low power consumption with OmniVision's best-in-class OmniPixel3-HS technology, enabling low-light performance of 3300 mV/lux-sec. Its 1/10-inch array is capable of operating up to 30 frames per second (FPS) in 400 x 400 HVGA or 60 FPS in 400 x 200 resolution, providing RAW serial output. The low-voltage OV6930 allows cabling up to 14 feet, and is now shipping in volume to multiple medical device customers.

For more information: www.ovt.com

 Reference:

(1) Leufkens AM, DeMarco DC, Siersema PD, et al. Effect of a Retrograde-Viewing Device on Adenoma Detection Rate during Colonoscopy: The "TERRACE" Study. Gastrointest Endosc 2011;73:480-9.

 

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...